Hims & Hers Health (HIMS) Operating Income (2019 - 2026)
Hims & Hers Health (HIMS) reported Operating Income of -$78.3 million for Q1 2026, down 235.28% on a YoY basis from $57.9 million in Q1 2025, and down 952.63% sequentially from $9.2 million in Q4 2025.
Hims & Hers Health (HIMS) Operating Income (2019 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 8 years of Operating Income data on file, last reported at -$78.3 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 235.28% year-over-year to -$78.3 million; the trailing twelve-month figure through Mar 2026 stood at -$30.6 million (down 127.85% YoY), and the FY2025 full-year result was $105.6 million, up 70.61% from the prior year.
- Operating Income retreated to -$78.3 million in Q1 2026, from $9.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $57.9 million in Q1 2025 to a low of -$78.3 million in Q1 2026.
- A 5-year average of -$526882.4 and a median of -$400000.0 in 2023 frame the typical range for Operating Income.
- Across the five-year window, Operating Income jumped 4749.0% in 2024 and sank 235.28% in 2026, its largest moves.
- Tracing HIMS's Operating Income over 5 years: stood at -$11.6 million in 2022, then surged by 96.55% to -$400000.0 in 2023, then jumped by 4749.0% to $18.6 million in 2024, then sank by 50.6% to $9.2 million in 2025, then tumbled by 952.63% to -$78.3 million in 2026.
- Business Quant data shows HIMS's Operating Income at -$78.3 million in Q1 2026, $9.2 million in Q4 2025, and $11.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 325.80 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | -78.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78.32 Mn |
| Dec 31, 2025 | 9.19 Mn |
| Sep 30, 2025 | 11.81 Mn |
| Jun 30, 2025 | 26.72 Mn |
| Mar 31, 2025 | 57.90 Mn |
| Dec 31, 2024 | 18.60 Mn |
| Sep 30, 2024 | 22.37 Mn |
| Jun 30, 2024 | 11.03 Mn |
| Mar 31, 2024 | 9.90 Mn |
| Dec 31, 2023 | -400,000.00 |
| Sep 30, 2023 | -8.55 Mn |
| Jun 30, 2023 | -9.24 Mn |
| Mar 31, 2023 | -11.26 Mn |
| Dec 31, 2022 | -11.61 Mn |
| Sep 30, 2022 | -19.98 Mn |
| Jun 30, 2022 | -20.19 Mn |
| Mar 31, 2022 | -16.92 Mn |
| Dec 31, 2021 | -21.57 Mn |
| Sep 30, 2021 | -27.66 Mn |
| Jun 30, 2021 | -17.41 Mn |